In summary, the results of our work suggest a strong therapeutic potential of diastereomer Esc(1–21)-1c in treating bacterial infection and concur to support further advanced preclinical studies aimed at developing it as a viable lead compound for the manufacture of new peptide-based formulation(s) for topical treatment of Pseudomonas lung infection.